The common misconception is that market access teams just set prices. In reality, they are a complete business leadership team with diverse expertise in health economics, strategy, and outcomes research. They must understand the entire business environment to demonstrate a therapy's value and ensure its commercial success, operating far beyond a simple pricing role.

When customers object to price, it's because they don't believe the value they'll receive will exceed the cost. The solution is not to discount, but to reinforce the return on investment using testimonials and case studies.

When a prospect pushes back on price, it's rarely about the absolute dollar amount. It's a symptom that they don't fully believe you can deliver the promised transformation or value. The salesperson's primary challenge is to build conviction in the outcome, which makes the price an easy decision in comparison.

Merck cited Cedara's extensive, pre-Phase 3 research on pricing and cost-effectiveness as a key factor in its $10B acquisition. This demonstrates that early-stage biotechs can significantly increase their M&A value by proactively building a robust commercial case alongside their clinical development.

Proposing an outcome-based pricing model next to a high fixed-fee option forces the negotiation to focus on value, not cost. Even if the customer chooses the fixed fee, they're anchored on a much higher number and are less likely to negotiate it down significantly.

Price objections don't stem from the buyer's ignorance, but from the seller's failure to establish clear economic value. Before revealing the cost, you must build a business case. If the prospect balks at the price, the fault lies with your value proposition, not their budget.

Effective pricing is not just a number; it is a value story. The ultimate test is whether a customer can accurately pitch your product's pricing and value proposition to someone else. This reframes pricing from a simple number to a compelling narrative.

For life sciences startups, UPMC's model shows that an integrated payer-provider views expensive therapies not just as a line-item cost but as a potential long-term saving. They calculate value based on reducing other system costs like hospital stays, supplemental drugs, or future procedures.

A one-time, $3 million gene therapy for Huntington's disease is more economical than the estimated $7-9 million lifetime cost of care. Insurance companies recognize this, as the treatment not only cuts costs but also allows patients to return to the workforce, contributing to the tax and insurance base.